653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials; treatment of NDMM and amyloidosis patients


Hartmut Goldschmidt, Elias K Mai, Eva Nievergall, et al.

This phase III study demonstrates the superiority of MRD negativity rates after induction by adding a CD38 moAb to RVd. There were no increased SAE rates or premature discontinuation.



Aurore Perrot, Valérie Lauwers-Cances, Cyrille Touzeau, et al.

D-IRD is a safe option for extended induction before and as consolidation after ASCT. This treatment allows for a gradual deepening of the response in standard risk MM. 39.5 percent of the patients achieved an MRD negativity 10-6 after consolidation. The 2-year PFS was 95.2 percent and the 2-year OS was 100 percent. Compared to D-VTD or D-KRD, the MRD negativity rates are lower.


465 ASH denotes this abstract as clinically relevant

Martin F. Kaiser, Andrew Hall, Katrina Walker, et al.

The intensified Dara combination therapy before and after ASCT for UHiR NDMM and pPCLOPTIMUM demonstrated a clear PFS advantage over the MyXI procedure after 18 months. The authors of the study suggest that Dara-VRd is particularly effective in maintaining the response after ASCT.


Laura Rosinol, Albert Oriol, Rafael Ríos Tamayo, et al.

Five years after starting maintenance therapy with lenalidomide and dexamethasone in patients treated homogeneously with VRD-GEM induction, ASCT, and VRD-GEM consolidation, the PFS was 63 percent. The addition of ixazomib did not result in a PFS benefit, in part presumably due to the higher, dose-reducing toxicity, which in part led to the discontinuation of ixazomib in the IRd arm.

Jason Valent, Jeffrey A. Zonder, Michaela Liedtke, et al.

CAEL-101 demonstrates good tolerability as part of an AL amyloidosis treatment strategy and confirms previous results on the use of CAEL-101 in combination with anti-PCD.